Skip to main content
PMC home page
PLOS Currents logoLink to PLOS Currents
. 2011 May 15;3:RRN1236. [Version 1] doi: 10.1371/currents.RRN1236

Thiopurine methyltransferase (TPMT) genotyping to predict myelosuppression risk

Christine M Nguyen *, Margaret AS Mendes *, Joseph D Ma *
PMCID: PMC3094768  PMID: 21593964

Abstract

Azathioprine (AZA), 6-mercaptopurine (6-MP), and thioguanine (TG) are thiopurine drugs. These agents are indicated for the treatment of various diseases including hematologic malignancies, inflammatory bowel disease (IBD), rheumatoid arthritis, and as immunosuppressants in solid organ transplants. Thiopurine drugs are metabolized, in part, by thiopurine methyltransferase (TPMT). TPMT displays genetic polymorphism resulting in null or decreased enzyme activity. At least 20 polymorphisms have been identified, of which, TPMT *2, *3A, *3B, *3C, and *4 are the most commonly studied. These polymorphisms have been associated with increased myelosuppression risk. TPMT genotyping may be useful to predict this risk.

Clinical Scenario

Approximately 86-97% of patients have the TPMT*1/*1 (wild-type) genotype.[1]  These patients have normal TPMT enzyme activity.  Approximately 3-14% of patients have the heterozygous TPMT genotype and possess one TPMT variant allele.  These patients may experience moderate to severe myelosuppression; therefore, thiopurine drug dose reduction may be warranted.[1] [2]  The population prevalence of patients who have the homozygous TPMT variant genotype is low (approximately 1 in 178 to 1 in 3,736 patients).[1]  However, these patients have the highest risk of developing severe myelosuppression, which may lead to life-threatening complications such as sepsis.[1] [2] [3]  These patients may not be candidates for treatment with a thiopurine drug, or the drug dose should be reduced by at least 10-fold.[1]

Test Description

The TPMT genotype assay uses polymerase chain reaction (PCR) amplication followed by single nucleotide primer extension to detect the TPMT*1, *2, *3A, *3B, and/or *3C alleles.[4] [5]  The TPMT genotype assay requires a whole blood sample.

Public Health Importance

Thiopurine-induced myelosuppression can result in increased morbidity, hospitalization and/or treatment discontinuation.[6] [7]  Myelosuppression increases an individual’s risk of developing an infection and sepsis.[8] [9] [10] [11]  The incidence of mild leukopenia is approximately 5-25%.[12]  Rare, but severe leukopenia can develop suddenly and unpredictably in approximately 3% of patients.[13]  A 27-year analysis showed that AZA contributed to the incidences of myelosuppression in 5% of patients.[10]  Over an 18-year period, 2% of patients with IBD experienced 6-MP-induced leukopenia that resulted in hospitalization.[14]  The incidence of myelosuppression occurred more frequently during the first eight weeks after treatment initiation, and was more likely to occur with a higher drug dose.[14] [15]  It should be noted that while the TPMT genotype test may predict myelosuppression risk, the test should not replace complete blood count (CBC) monitoring to detect myelosuppression during treatment with thiopurine drugs.[2] [16]  Given that TG carries the risk of myelosuppression[17], CBC monitoring is also necessary for this drug. 

Published Reviews, Recommendations and Guidelines 

Systematic evidence reviews

The Agency for Healthcare Research and Quality (AHRQ) concluded that “there is currently insufficient evidence regarding the effectiveness of determining TPMT status prior to thiopurine treatment in terms of improvement in clinical outcomes and incident myelotoxicity in comparison with routine monitoring of full blood counts and adverse events."[2]


Recommendations by independent groups

  • The Clinical Pharmacogenomics Implementation Consortium (CPIC) guidelines:[1]
    • Heterozygous TPMT genotype (intermediate activity): In patients who possess a single TPMT functional (*1) and nonfunctional allele (*2, *3A, *3B, *3C, or *4), the initial dose of AZA or 6-MP should be reduced by 30-70%.  The AZA dose can be titrated as tolerated.  The 6-MP dose should be adjusted based on the severity of myelosuppression and disease-specific guidelines.  The initial dose of TG should be reduced by 30-50%, and adjusted based on the severity of myelosuppression and disease-specific guidelines.
    • Homozygous TPMT genotype (variant mutant, low, or deficient activity): Reduce the initial dose of AZA, 6-MP or TG by 10-fold and extend the dosing frequency from daily to three times weekly, or select an alternative drug.
  • The Royal Dutch Association for the Advancement of Pharmacy Pharmacogenomic Working Group:[18]
    • Patients who are intermediate metabolizers based on the TPMT genotype or phenotype test: The dose of AZA or 6-MP should be reduced by 50% and titrated based on hematologic monitoring and efficacy, or select an alternative drug. 
    • Patients who are poor metabolizers based on the TPMT genotype or phenotype test: The dose of AZA or 6-MP should be reduced by 90% and titrated based on hematologic monitoring and efficacy, or select an alternative drug.
    • Patients who are intermediate or poor metabolizers should not be treated with TG as there are “insufficient data to allow calculation of dose adjustment.”

Guidelines by professional groups

  • The American College of Gastroenterology treatment guidelines prefer TPMT phenotyping over genotyping because the phenotype assay quantifies the level of TPMT enzyme activity in patients who are being treated with thiopurines for ulcerative colitis (UC).[16]

  • The British Society of Gastroenterology does not require either TPMT genotyping or phenotyping as a prerequisite to initiating thiopurine therapy because the use of AZA has been shown to be safe in patients with Crohn’s disease (CD) or UC.[13] [19]    

Other groups

  • The US Food and Drug Administration (FDA) and prescribing information for AZA and 6-MP recommend either TPMT genotyping or phenotyping prior to initiating therapy to help identify patients who are at an increased risk of developing toxicity.[20] [21] [22]

  • The prescribing information for TG indicates that patients with TPMT deficiency “may be unusually sensitive to the myelosuppressive effects of TG.  Substantial dosage reductions may be required to avoid the development of life-threatening bone marrow suppression.  Prescribers should be aware that some laboratories offer testing for TPMT deficiency.”[17]  Despite the risk of myelosuppression and the availability of TPMT tests, the manufacturer does not indicate that testing for TPMT deficiency prior to initiating TG is recommended, or provide dose adjustment guidance based on the TPMT test result.

Evidence Overview 

Analytic Validity

      A systematic review of published literature was conducted to determine the characteristics of the TPMT tests.[23]  The literature evaluated TPMT tests in patients with various ethnicities (e.g., Caucasians, Asians, and African Americans).  The patient population analyzed was non-specific; healthy volunteers, those with medical conditions that require thiopurine (e.g., acute lymphoblastic leukemia, IBD), children, and adults were included.  The results showed that there are eight different ways in which the TPMT genotype tests can be performed, and no single "gold standard" method for comparison has been accepted.  Overall, the TPMT genotype tests had a lower sensitivity and a higher positive predictive value (PPV) in comparison to the TPMT phenotype test.  Furthermore, there was a wide range of sensitivity, specificity, PPV and negative predictive value (NPV), which could be due to the variety of genotyping methods.  Additionally, these ranges were derived from evaluations of genotype testing methods compared with various reference standards that included both genotyping and enzymatic tests.

  • Sensitivity: 55-100%

  • Specificity: 94-100%

  • PPV: 67-100%

  • NPV: 76-100%

Clinical Validity

  • Patients with homozygous TPMT (inactive) genotype who are treated with conventional doses of thiopurines have 100% likelihood of developing severe myelosuppression.[1]  The odds ratio (OR) of developing leukopenia is 18.60 (95% CI = 4.12-83.60).[2]

  • Approximately 30-60% of patients with heterozygous TPMT genotype experience severe myelosuppression when standard doses of thiopurines are administered.[1]  The OR of developing leukopenia is 4.62 (95% CI = 2.34-9.16).[2]

  • Approximately 6-11% of Caucasians have the heterozygous TPMT genotype, and 0.03% have the homozygous variant TPMT genotype.[24] [25] [26] [27]  Southeast Asians and Japanese have a lower rate of the heterozygous TPMT genotype (1.2-2%) and homozygous variant TPMT genotype (<1%).[28] [29]

  • Concordance between TPMT genotype and phenotype vary in the published literature.  One study showed that approximately 43% of IBD patients who possess one TPMT variant allele had increased TPMT enzyme activity.[30]  In another study, the correlation between TPMT phenotype and genotype was 99% amongst patients with IBD who were treated with AZA.[31]

Clinical Utility

  • No studies were identified that directly address clinical utility in regards to improving health outcomes (e.g., mobidity and mortality).

  • Although patients with the TPMT wild-type genotype are less likely to experience leukopenia, some patients may experience this adverse event at a rate ranging from 8% to 43%, which leads to either dose reduction or treatment discontinuation.[28] [30] [32] [33] [34] [35]  Conversely, patients with the heterozygous TPMT genotype may not experience myelosuppression at all.[32] [34] [36]

  • Approximately 71-91% of patients with the heterozygous TPMT genotype do not experience severe leukopenia, and 25% of patients with the homozygous variant TPMT genotype do not experience severe leukopenia.[32] [34]

  • The TPMT genotype test is designed to detect a limited number of mutations.  Therefore, it cannot be considered the gold standard to determine TPMT activity.[23]

  • From a third-party payer’s perspective, a one-year cost-effectiveness analysis reported that implementing the TPMT genotyping is cost-effective versus standard of care in patients with chronically active steroid-treated CD.[37]  Patients achieved a quicker response time compared to standard of care (19.19 weeks vs. 22.41 weeks).

Clinical Considerations

      TPMT genotype status is not the sole reason for increased myelosuppression risk in patients who are treated with thiopurine drugs.  Myelosupprression may be the result of drug-drug interactions with agents such as, but not limited to, allopurinol, mesalamine, metronizadole, non-steroidal anti-inflammatory drugs (NSAIDs), and sulfamethoxazole/trimethoprim.[24]

Links


Funding information

Christine M. Nguyen and Margaret A.S. Mendes are funded by the Veterans Affairs San Diego Healthcare System. Joseph D. Ma is funded by the University of California, San Diego Skaggs School of Pharmacy and Pharmaceutical Sciences.
 

Competing interests

The authors have declared that no competing interests exist.


References

  1. Relling MV, Gardner EE, Sandborn WJ, et al. Clinical pharmacogenetics implementation consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing. Clin Pharmacol Ther 2011;89(3):387-91. Epub 2011 Jan 26. [DOI] [PMC free article] [PubMed]
  2. Agency for Healthcare Research and Quality. Evidence report/technology assessment (number 196): assessment of thiopurine methyltransferase activity in patients prescribed azathioprine or other thiopurine-based drugs. Available at: http://www.ahrq.gov/clinic/tp/tpmttp.htm#Report. Accessed 24 Feb 2010. [PMC free article] [PubMed]
  3. Regueiro M, Mardini H. Determination of thiopurine methyltransferase genotype or phenotype optimizes initial dosing of azathioprine for the treatment of Crohn’s disease. J Clin Gastroenterol 2002:35(3):240-244. [DOI] [PubMed]
  4. Quest Diagnostics. TPMT genotype. Available at: http://www.questdiagnostics.com/hcp/intguide/jsp/showintguidepage.jsp?fn=Immuno/TS_TPMT_Genotype.htm. Accessed on 23 Sept 2010.
  5. Sonora Quest Laboratories. TPMT genotype. Available at: http://www.sonoraquest.com/test-information/tpmt-genotype/. Accessed 24 Feb 2011.
  6. Leung M, Piatkov I, Rochester C, et al. Normal thiopurine methyltransferase phenotype in a Crohn disease patient with azathioprine induced myelosuppression. Intern Med J 2009;39:121-126. [DOI] [PubMed]
  7. Ugajin T, Miyatani H, Demitsu T, et al. Severe myelosuppression following alopecia shortly after the initiation of 6-mercaptopurine in a patient with Crohn’s disease. Intern Med 2009;48(9):693-695. [DOI] [PubMed]
  8. Campbell S, Gosh S. Is neutropenia required for effective maintenance of remission during azathioprine therapy in inflammatory bowel disease? Eur J Gastroenterol Hepatol 2001;13(9):1073-1076. [DOI] [PubMed]
  9. Posthuma EE, Westendorp RG, van der Sluvs VA, et al. Fatal infectious mononucleosis: a severe complication in the treatment of Crohn’s disease with azathioprine. Gut 1995;36(2):311-313. [DOI] [PMC free article] [PubMed]
  10. Connell WR, Kamm MA, Ritchie JK, et al. Bone marrow toxicity caused by azathioprine inflammatory bowel disease: 27 years of experience. Gut 1993;34:1081-1085. [DOI] [PMC free article] [PubMed]
  11. Schütz E, Gummert J, Mohr F, et al. Azathioprine-induced myelosuppression in thiopurine methyltransferase deficient heart transplant recipient. Lancet 1993;341:436. [DOI] [PubMed]
  12. Gurwitz D, Rodríguez-Antona C, Payne K, et al. Improving pharmacovigilance in Europe: TPMT genotyping and phenotyping in the UK and Spain. Eur J Hum Genet 2009;17(8):991-998. [DOI] [PMC free article] [PubMed]
  13. Carter MJ, Lobo AJ, Travis SP, et al. Guidelines for the management of inflammatory bowel disease in adults. Guts 2004;53(Suppl 5):v1-16. [DOI] [PMC free article] [PubMed]
  14. Present DH, Meltzer SJ, Krumholz MP, et al. 6-mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity. Ann Intern Med 1989;111(8):641-649. [DOI] [PubMed]
  15. Lewis JD, Abramson O, Pascua M, Liu L, Asakura LM, Velayos FS, et al. Timing of myelosuppression during thiopurine therapy for inflammatory bowel disease: implications for monitoring recommendations. Clin Gastroenterol Hepatol 2009:7(11);1195-1201. [DOI] [PMC free article] [PubMed]
  16. Korbluth A, Sachar DB and the Practice Parameters Committee of the American College of Gastroenterology. Erratum: ulcerative colitis practice guidelines in adults: American College of Gastroenterology, Practice Paremeters Committee. Ams J Gastroenterol 2010;105:500-523. [DOI] [PubMed]
  17. Tabloid [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2004.
  18. Swen JJ, Nijenhuis M, de Boer A, et al. Pharmacogenetics: from bench to byte-an update of guidelines. Clin Pharm Ther 2011 ;89(5):662-673. [DOI] [PubMed]
  19. Ford LT, Berg JD. Thiopurine S-methyltransferase (TPMT) assessment prior to starting thiopurine drug treatment: a pharmacogenomic test whose time has come. J Clin Pathol 2010;63:288-295. [DOI] [PubMed]
  20. Imuran [package insert]. San Diego, CA: Prometheus Laboratories, Inc.; 2009.
  21. Purinethol [package insert]. Greenville, NC: DSM Pharmaceuticals, Inc.; 2003.
  22. US Food and Drug Administration. Table of pharmacogenomics markers. Available at: http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm083378.htm. Accessed 24 Feb 2011.
  23. Donnan JR. Ungar WJ, Matthews M, et al. Systematic review of thiopurine methyltransferase genotype and enzymatic testing strategies. Ther Drug Monit 2011;33(2):192-199. [DOI] [PubMed]
  24. Al Hadithy AF, de Boer NK, Derijks Lj, et al. Thiopurines in inflammatory bowel disease: pharmacogenetics, therapeutics, drug monitoring and clinical recommendations. Dig Liv Dis 2005;37:282;297. [DOI] [PubMed]
  25. Gearry RB, Barclay ML, Roberts RL, et al. Thiopurine methyltransferase and 6-thioguanine nucleotide measurement: early experience of use in clinical practice. Intern Med J 2005;35(10):580-585. [DOI] [PubMed]
  26. Mascheretti S, Croucher PJ, Schreiber S. Pharmacogenetics of inflammatory bowel disease. Best Pract Res Clin Gastroenterol 2004;18(3):597-609. [DOI] [PubMed]
  27. Corominas H, Domènech M, González D, et al. Allelic variants of the thiopurine S-methyltransferase deficiency in patients with ulcerative colitis and in healthy control. Am J Gastroenterol 2000;95(9):2131-2317. [DOI] [PubMed]
  28. Takatsu N, Matsui T, Murakami Y, et al. Adverse reactions to azathioprine cannot be predicted by thiopurine s-methyltransferase genotype in Japanese patients with inflammatory bowel disease. J Gastroenterol Hepatol 2009;24(7):1258-1264. [DOI] [PubMed]
  29. Chang J, Lee L, Chen C, et al. Molecular analysis of thiopurine S-methyltransferase alleles in South-east Asian populations. Pharmacogenetics 2002;12:191-195. [DOI] [PubMed]
  30. Schwab M, Schäffeler E, Marx C, et al. Azathioprine therapy and adverse drug reactions in patients with inflammatory bowel disease: impact of thiopurine S-methyltransferase polymorphism. Pharmacogenetics 2002;12(6):429-436. [DOI] [PubMed]
  31. Ansari A, Arenas M, Greenfield SM, et al. Prospective evaluation of the pharmacogenetics of azathioprine in the treatment of inflammatory bowel disease. Aliment Pharmacol Ther 2008;28(8):973-983. [DOI] [PubMed]
  32. Colombel JF, Ferrari N, Debuysere H, et al. Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn’s disease and severe myelosuppression during azathioprine therapy. Gastroenterology 2000;118(6):1025-1030. [DOI] [PubMed]
  33. Vannaprasaht S, Angsuthum S, Avihingsanon Y, et al. Impact of heterozygous TPMT*1/*3C genotype on azathioprine-induced myelosuppression in kidney transplant recipients in Thailand. Clin Ther 2009;31:31(7):1524-1533. [DOI] [PubMed]
  34. Winter JW, Gaffney D, Shapiro D, et al. Assessment of thiopurine methyltransferase enzyme activity is superior to genotype in predicting myelosuppression following azathioprine therapy in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2007;25(9):1069-1077. [DOI] [PubMed]
  35. Kurzawski M, Dziewanowski K, Gawrońska-Szklarz B, et al. The impact of thiopurine S-methyltrasferase polymorphism on azathioprine-induced myelotoxicity in renal transplant patients. Ther Drug Monit 2005;27(4):435-441. [DOI] [PubMed]
  36. Kolorz M, Bartosova L, Hosek J, et al. Importance of thiopurine S-methyltransferase gene polymorphisms for prediction of azathioprine toxicity. Neuro Endocrinol Lett 2009;30(Suppl 1):137-142. [PubMed]
  37. Dubinsky MC, Reyes E, Ofman J, et al. A cost-effectiveness analysis of alternative disease management strategies in patients with Crohn’s disease treated with azathioprine or 6-mercaptopurine. Am J Gastroenterol 2005;100(10):2239-2247. [DOI] [PubMed]

Articles from PLoS Currents are provided here courtesy of PLOS

RESOURCES